AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
As of 01:23PM BST. Market open.
| Previous Close | 10,914.00 |
| Open | 10,914.00 |
| Bid | 10,866.00 x 0 |
| Ask | 10,868.00 x 0 |
| Day's Range | 10,764.00 - 10,934.00 |
| 52 Week Range | 9,461.00 - 12,348.00 |
| Volume | |
| Avg. Volume | 2,896,782 |
| Market Cap | 168.448B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 35.51 |
| EPS (TTM) | 3.06 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 2.28 (2.09%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | 125.30 |
ZacksAstrazeneca (AZN) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
ZacksAstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
© 2024 Yahoo. All rights reserved.